Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Interventional × inavolisib × Clear all

Phase

Status

Recruiting 14 Active not recruiting 5 Not yet recruiting 2 Withdrawn 1 Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasm Metastasis 1

Interventions

Cyclophosphamide 1235 Cisplatin 1164 Paclitaxel 1083 Radiotherapy 1067 Carboplatin 1030 Gemcitabine 1014 Docetaxel 938 Bevacizumab 855 Fluorouracil 738 Doxorubicin 664 Dexamethasone 622 Capecitabine 615 Rituximab 595 Oxaliplatin 576 Etoposide 563 pembrolizumab 540 Filgrastim 528 Irinotecan 527 Cytarabine 488 Leucovorin 478 Nivolumab 437 Vincristine 426 Prednisone 393 Bortezomib 392 Cetuximab 385 Erlotinib Hydrochloride 382 Trastuzumab 373 Methotrexate 354 Pemetrexed 350 Lenalidomide 350

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04551521 2025-01-08

CRAFT: The NCT-PMO-1602 Phase II Trial

German Cancer Research Center

Phase 2 Completed

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡